J&J Names CEO Designate of Planned Consumer Health Spin-off

Johnson & Johnson (J&J) has named Thibaut Mongon, Executive Vice President and Worldwide Chairman of Consumer Health at J&J, as CEO Designate of J&J’s to-be-spun-off, new Consumer Health company.

J&J announced plans last November (November 2021) to split the company into two separate, standalone, publicly traded companies, one focused on pharmaceuticals and medical devices, and the other on consumer health. The planned separation of the two companies is expected to occur within 2023.

The leadership transition to Consumer Health’s new CEO will occur upon completion of the planned separation of the Consumer Health business, expected to occur within 2023, subject to legal requirements, including consultation with works councils and employee representatives. J&J says directors and additional executive leadership appointments will be determined in the coming months (as reported on May 11, 2022) as the planned separation process progresses.

With more than 20 years at J&J, Mr. Mongon has served as Executive Vice President and Worldwide Chairman of Consumer Health at J&J since 2019. Mr. Mongon is responsible for leading portfolios of consumer health products with brands including, Tylenol, Neutrogena, Aveeno, Listerine, and Johnson’s.

In addition, Paul Ruh, currently Chief Financial Officer (CFO) of J&J’s Consumer Health business has been named Chief Financial Officer Designate of the new Consumer Health company. He joined J&J five years ago in his current role and prior to joining J&J, held leadership roles with PepsiCo, McKinsey & Company, and Procter & Gamble.

Source: Johnson & Johnson